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Compounds belonging to a carbazole series have been identified as potent fungal plasma membrane
proton adenosine triphophatase (H+-ATPase) inhibitors with a broad spectrum of antifungal activity.
The carbazole compounds inhibit the adenosine triphosphate (ATP) hydrolysis activity of the essential
fungal H+-ATPase, thereby functionally inhibiting the extrusion of protons and extracellular acidification,
processes that are responsible for maintaining high plasma membrane potential. The compound class
binds to and inhibits the H+-ATPase within minutes, leading to fungal death after 1–3 h of compound
exposure in vitro. The tested compounds are not selective for the fungal H+-ATPase, exhibiting an overlap
of inhibitory activity with the mammalian protein family of P-type ATPases; the sarco(endo)plasmic
reticulum calcium ATPase (Ca2+-ATPase) and the sodium potassium ATPase (Na+,K+-ATPase). The ion
transport in the P-type ATPases is energized by the conversion of ATP to adenosine diphosphate (ADP)
and phosphate and a general inhibitory mechanism mediated by the carbazole derivative could therefore
be blocking of the active site. However, biochemical studies show that increased concentrations of ATP do
not change the inhibitory activity of the carbazoles suggesting they act as allosteric inhibitors.
Furthermore decreased levels of intracellular ATP would suggest that the compounds inhibit the
H+-ATPase indirectly, but Candida albicans cells exposed to potent H+-ATPase-inhibitory carbazoles result
in increased levels of intracellular ATP, indicating direct inhibition of H+-ATPase.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Each year, 2 million people contract an invasive fungal infection
(IFI) worldwide, and with mortality rates reaching 95% depending
on the pathogen and underlying risk factors, IFIs represent a signif-
icant public health problem.1 Despite a rising number of emerging
invasive fungal pathogens, the majority of IFI’s are caused by the
yeast Candida albicans and the mold Aspergillus fumigatus. Can-
didemia (caused by Candida spp.) is among the top 5 most common
nosocomial blood-borne infections in the US.2 Individuals most at
risk of developing life-threatening fungal infections are those on
immunosuppressive therapies, aggressive chemotherapies, HIV-
infected patients and those with congenital immunodeficiencies
(e.g. chronic granulomatous disease).3 Continuous advances in sur-
gical procedures, organ transplantation medicine and chemothera-
peutic regimens, as well as ongoing resistance development
coincides with an increase in the incidence of difficult-to-treatinvasive fungal disease.4,5 Current antifungal treatments represent
3 main compound classes; the polyenes (e.g. amphotericin B), the
azoles (e.g. voriconazole, fluconazole), and the echinocandins
(e.g. caspofungin). These current therapies collectively suffer from
shortfalls such as toxicity, drug-drug interactions, narrow spec-
trum of activity, and resistance development. Furthermore, the
emergence of multidrug-resistant Candida and Aspergillus isolates
is an increasing concern.6 Besides the inherent limitations in the
current compound classes, initiation of appropriate treatment is
often delayed by challenges in diagnosis.7 Therefore, new classes
of safe, well-tolerated broad-spectrum antifungal drugs without
drug-drug interactions and a propensity for resistance are urgently
needed.8
The fungal plasma membrane H+-ATPase is essential for fungal
growth and survival.9 The H+-ATPase is a proton pump, generating
the electrochemical gradient across the fungal plasma membrane
by transporting protons from the cytoplasm to the extracellular
site. This process is energized by the conversion of ATP to ADP
and phosphate. Fungal plasma membrane proton pumps belong
to the PIII-type ATPase family,10 and the H+-ATPase is highly
Table 1
IC50 determination of the H+-ATPase inhibition and minimal inhibitory concentration
determination (MIC) of fungal growth by initial hit compounds 1–4.
ATP hydrolysis IC50 [mM] Fungal Growth Inhibition MIC [mM]
S. cerevisiae H+-ATPase S. cerevisiae C. albicans
1 18.8 ± 7.3 >200 >200
2 5.5 ± 0.7 50 >200
3 9.7 ± 0.6 50 100
4 17.3 ± 5.5 10 30
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tity between the H+-ATPase in different Candida species. In mam-
malian cells, the functionally related PII-type Na+,K+-ATPase is
responsible for maintaining the ion gradient across the plasma
membrane.11,12 The sequence identity of the H+-ATPase to the
mammalian PII-type ATPases, Na+,K+-ATPase and the sarcoplasmic
reticulum Ca2+-ATPase, is less than 30%. The activity of the Na+,K+-
ATPase is targeted with cardiotonic steroids (CTS) in the treatment
of congestive heart failure.13 The Ca2+-ATPase has been identified
as a promising anticancer target using a pro-drug approach with
the highly potent and specific Ca2+-ATPase inhibitor thapsigargin.14
The essential nature of the conserved fungal H+-ATPase, which is
absent from mammalian cells, makes it an attractive target for
the development of novel broad-spectrum antifungal agents.
In the search for novel H+-ATPase inhibitors, a library screen of
20,240 small molecule compounds was conducted by screening for
H+-ATPase inhibitory activity at a compound concentration of
20 mM. Four compounds containing an N1-substituted carbazole
moiety were identified from the library screening as novel H+-
ATPase inhibitors (Fig. 1), and the ATP hydrolysis IC50 was deter-
mined together with antifungal activity against S. cerevisiae and
C. albicans (Table 1). Compound 4 was the most potent antifungal
compound, which displayed H+-ATPase inhibitory activity.
It seemed plausible from the limited structure-activity relation-
ship available that the chloro substitutions of R1 and R2, possibly in
combination with some size exclusion in R4, were driving the cel-
lular activity (comparing compound 4with 1 and 2, and compound
4 with compound 3, respectively), given that the ATP hydrolysis
IC50 was similar for all four compounds. Based on this hypothesis
fifteen compounds were synthesized to further explore the struc-
ture-activity relationship (Figs. 2–4). The compounds were charac-
terized for H+-ATPase inhibition and antifungal activity by means
of an ATP hydrolysis assay and a fungal growth inhibition assay,
respectively. Furthermore a study was conducted to investigate if
the binding site of the compounds overlapped with the nucleo-
tide-binding site within the H+-ATPase, and to investigate possible
effects on the intracellular ATP level in C. albicans. Additionally, the
ability of selected compounds to inhibit acidification of the sur-
rounding media of fungal cells after addition of glucose was inves-
tigated. Finally, we determined whether the compounds acted in a
fungistatic or a fungicidal manner.
To investigate the H+-ATPase inhibitory effect of the compounds
we isolated plasma membranes containing H+-ATPase from S. cere-
visiae and C. albicans cells.15 Plasma membranes isolated from pig
kidney as well as endoplasmic reticulum membranes from rabbit
hind leg muscle were used to counter-screen compounds for activ-
ity against mammalian Na+,K+-ATPase and Ca2+-ATPase, respec-
tively. Prior to their use, fungal plasma membrane batches were1
4
2
3
Fig. 1. Carbazole scaffold (left) and structures of initial H+-ATPase inhibitor hits 1–4.
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the pH optimum of the ATPase activity, and the sensitivity to inhi-
bition by orthovanadate. ATPase activity was determined by a col-
orimetric assay that measures the amount of inorganic phosphate
liberated over time, as described in Kjellerup et al., 2017.15 Tables
2–4 list the IC50 values obtained by measuring the concentration
dependence of the ATPase activity for the fifteen carbazole com-
pounds with each of the four membrane preparations.
Compared to the parent compounds 1–4, compound 10 exhib-
ited the highest potency for H+-ATPase inhibition, with IC50 values
of 1.1 and 2 mM for C. albicans and S. cerevisiae H+-ATPase, respec-
tively, i.e. up to ca. 9-fold more potent than the parent compounds.
H+-ATPase inhibition was generally 2-fold lower for the
C. albicans H+-ATPase than for the S. cerevisiae H+-ATPase. It should
be considered, however, that this difference need not necessarily
reflect a difference in the affinity of the compounds for the two
fungal H+-ATPases, but may reflect different functional properties
of the pumps themselves. Provided that the compounds inhibit
the pumps by binding to a specific protein conformational state
in the transport cycle (for P-type pumps this is commonly referred
to as the E1-E2 cycle16), a lower IC50 would also be expected if that
particular conformational state was more prevalent or long-lived
in the cycle for one protein compared to the other. Such differences
may come about by variations in the degree of post-translational
modification levels.17 A similar argument can be made with
respect to the differences in IC50 values between the fungal
(PIII-type) and the two mammalian pumps (PII-type). Nevertheless,
the majority of the compounds do not exhibit selectivity for either
fungal or the mammalian ATPases, inhibiting all four enzymes with
similar IC50 values, with a few notable exceptions. For instance, 9
and 12 displayed pronounced selectivity towards Na+,K+-ATPase
(i.e. lower IC50 value) and could be an interesting starting point
in the pursuit of a specific Na+,K+-ATPase inhibitor (Tables 2 and
3). Additionally, 18 and 19 were much less potent on the Ca2+-
ATPase than the three other pumps (Table 3). However, in general,
the carbazole series shows little discrimination in its inhibition of
PII- and PIII-type ATPases. Initially, we attempted to explore varia-
tions in R4. Noting that the basic center in R4 was not a prerequisite
for ATPase inhibitory activity (c.f. compound 2 and 3), we prepared
analogues of compound 4 with a range in pKa (Fig. 2). Compound
10 was by far the most potent ATPase inhibitor and antifungal
compound, supporting the notion that the basic moiety (com-
pounds 4 and 10) with an (flexible) apolar terminal chain b to
the hydroxy group (compounds 6, 7 and 10) is preferred for opti-Table 2
IC50 determination of ATPase inhibition and MIC (MFC) determination of fungal growth o
Compound ATP hydrolysisa IC50 [mM]
S. cerevisiae H+-ATPase C. albicans H+-ATPase
5 23.0 ± 12.3 19.3 ± 2.6
6 7.4 ± 1.6 4.0 ± 1.2
7 6.9 ± 1.3 2.6 ± 0.4
8 52.7 ± 10.6 26.4 ± 2.5
9 106.8 ± 11.8 105.3 ± 13.9
10 2.0 ± 0.2 1.1 ± 0.2
Fungal Growth Inhibition MIC (MFC) [mM]
Saccharomyces cerevisiae ATCC 9763 Candida albicans SC5314 Candid
5 24 (75) 24 (>75) >75 (>
6 75 (>75) 75 (>75) >75 (>
7 24 (24) 75 (75) >75 (>
8 7.5 (7.5) 68 (75) 75 (>7
9 >75 (>75) >75 (>75) >75 (>
10 0.4 (1.2) 3.7 (3.8) 2.9 (3.
a ATP hydrolysis data determined at pH 7 (n = 3).mal activity. The more drug-like compound 8, with moderate
ATPase and fungal inhibitory activity, was chosen as a template
to explore the importance of substitutions in R1 and R2. It was
already determined (compounds 1–3) that substitution was not
required for activity and that a lipophilic substitution could poten-
tially increase antifungal activity. We decided to explore this
notion more broadly by preparing analogues with small and highly
polar substitutions capable of making hydrogen bonds (com-
pounds 11–13, Fig. 3). All three resulting compounds exhibited a
complete loss of both H+-ATPase inhibitory activity and antifungal
activity (Table 3).
Finally, we proceeded to investigate the importance of the alky-
loxy group using the same piperazine template (compound 16) as
before. We discovered that we could either simplify the terminal
apolar chain (compounds 14 and 15) or increase the chain (com-
pounds 17 and 19) with no dramatic change in activity (Fig. 4,
Table 4). In conclusion, an effort was made to explore the pharma-
cophore for the carbazole series, which revealed that polar substi-
tutions at R1 and R2 resulted in loss of the H+-ATPase inhibitory
activity, hydrogen at R3 improved H+-ATPase inhibitory activity
as compared to a hydroxyl-group (comparing compound 16 with
8), and substitutions of different length in R4 was allowed. Addi-
tional work could include ring opening of the carbazole core to
decrease possible p-stacking (and aggregation), as well as trying
to generate stronger interactions in the N1-chain in order to
increase overall potency of the carbazole series and realize ATPase
specificity for H+-ATPase.
To investigate whether the ATPase inhibition observed was due
to compound binding at the ATP binding site, three compounds (5,
7, and 10) were selected for further evaluation in an ATPase activ-
ity assay on S. cerevisiae H+-ATPase-containing membranes in pres-
ence of increasing ATP concentrations. The initial rate of ATP
turnover was measured spectrophotometrically by an NADH-cou-
pled ATPase activity assay that uses phosphoenolpyruvate to
regenerate ATP, as described in Møller et al., 1980.18 Fig. 5 shows
representative data from the spectrophotometric traces obtained
with 5 mM ATP in the reaction buffer containing either DMSO or
inhibitory concentrations of 5, 7 or 10. DMSO alone had no effect
on the initial rate of ATP hydrolysis, whereas the three compounds
significantly and rapidly reduced the rate of ATP hydrolysis.
In Fig. 6, the initial rate of ATP hydrolysis, obtained in similar
experiments carried out in the presence of either 1 or 10 mM
ATP, is plotted as a function of compound concentration. The max-
imal rate of ATPase activity in the absence of compound increasedf initial hit compounds 5–10.
Mammalian Ca2+-ATPase Mammalian Na+,K+-ATPase
10.7 ± 2.2 20.4 ± 2.3
20.3 ± 3.6 5.2 ± 0.3
19.6 ± 7.2 6.0 ± 1.3
36.8 ± 12.2 9.7 ± 3.3
97.6 ± 25.7 4.0 ± 0.7
0.3 ± 0.1 1.0 ± 0.2
a krusei ATCC 6258 Candida glabrata ATCC 90030 Candida glabrata Cg003
75) >75 (>75) >75 (>75)
75) >75 (>75) >75 (>75)
75) >75 (>75) >75 (>75)
5) 42 (75) 58 (75)
75) >75 (>75) >75 (>75)
8) 1.2 (3.8) 5.6 (7.9)
Table 3
IC50 determination of ATPase inhibition and MIC (MFC) determination of fungal growth of initial hit compounds 11–13.
Compound ATP hydrolysisa IC50 [mM]
S. cerevisiae H+-ATPase C. albicans H+-ATPase Mammalian Ca2+-ATPase Mammalian Na+,K+-ATPase
11 >167 >167 >167 >167
12 >167 144.1 ± 14.7 92.7 ± 13.1 10.5 ± 1.4
13 >167 >167 >167 >167
Fungal Growth Inhibition MIC (MFC) [mM]
Saccharomyces cerevisiae ATCC 9763 Candida albicans SC5314 Candida krusei ATCC 6258 Candida glabrata ATCC 90030 Candida glabrata Cg003
11 >75 (>75) >75 (>75) >75 (>75) >75 (>75) >75 (>75)
12 >75 (>75) >75 (>75) >75 (>75) >75 (>75) >75 (>75)
13 >75 (>75) >75 (>75) >75 (>75) >75 (>75) >75 (>75)
a ATP hydrolysis data determined at pH 7 (n = 3).
Table 4
IC50 determination of ATPase inhibition and MIC (MFC) determination of fungal growth of initial hit compounds 14–19.
Compound ATP hydrolysisa IC50 [mM]
S. cerevisiae H+-ATPase C. albicans H+-ATPase Mammalian Ca2+-ATPase Mammalian Na+,K+-ATPase
14 36.2 ± 3.1 23.3 ± 5.3 13.0 ± 2.1 2.1 ± 0.5
15 51.8 ± 0.5 31.1 ± 4.8 17.5 ± 11.4 5.1 ± 0.8
16 20.0 ± 1.0 7.1 ± 0.5 23.2±6.4 2.5 ± 0.6
17 18.7 ± 2.4 15.4 ± 2.6 17.5 ± 2.1 4.7 ± 0.9
18 11.1 ± 3.8 5.9 ± 1.7 70.9 ± 8.4 7.7 ± 3.1
19 24.9±1.8 11.6 ± 1.6 95.4 ± 20.5 5.6 ± 0.5
Fungal Growth Inhibition MIC (MFC) [mM]
Saccharomyces cerevisiae ATCC 9763 Candida albicans SC5314 Candida krusei ATCC 6258 Candida glabrata ATCC 90030 Candida glabrata Cg003
14 5.8 (16) 24 (75) 13 (24) 24 (24) 24 (75)
15 2.4 (5) 24 (24) 7.5 (16) 7.5 (7.5) 7.5 (24)
16 2.4 (2.4) 24 (24) 7.5 (7.5) 7.5 (7.5) 7.5 (7.5)
17 2.4 (2.4) 24 (24) 7.5 (7.5) 7.5 (7.5) 7.5 (24)
18 >75 (>75) >75 (>75) >75 (>75) >75 (>75) >75 (>75)
19 7.5 (7.5) >75 (>75) >75 (>75) 24 (>75) 24 (>75)
a ATP hydrolysis data determined at pH 7 (n = 3).
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1 mM ATP is not saturating for the transport activity. The IC50 val-
ues for the compounds did not increase appreciably despite the 10-
fold increase in ATP concentration, suggesting that the binding site
for the compounds does not overlap with that of ATP at the nucleo-
tide-binding site, and, hence, that the compounds act as allosteric
inhibitors. Importantly, the three compounds display a similar rel-
ative pattern in the two ATPase assays, with compound 10 display-
ing the lowest IC50 and compound 5 the highest IC50.
We subsequently assessed the carbazole series for antifungal
activity, as described in Kjellerup et al., 2017.15 Tables 2–5 list
the minimum inhibitory concentrations (MIC) and the minimum
fungicidal concentrations (MFC) of the fifteen compounds tested
against the yeasts Saccharomyces cerevisiae, Candida albicans, C.
krusei, and two isolates of C. glabrata (a wild-type strain ATCC
90030 and a clinical azole-resistant isolate Cg003 with increased
efflux pump expression19), and the molds Aspergillus fumigatus
and A. flavus. MIC was defined as the lowest concentration inhibit-
ing visual growth of the microorganism in RPMI-1640 media. Com-
pound 10, the most potent ATPase inhibitor, was also the most
potent antifungal compound, with MIC values ranging from 0.4
to 12 mM on all fungal isolates tested, in comparison to MICs of
30 mM and above against C. albicans for compounds 1–4. Although
10 exhibited a 5-fold higher MIC against the azole-resistant than
the wild-type C. glabrata isolate, it is encouraging to see activity
against this isolate, despite its overexpression of the multidrugresistance efflux pumps Cdr1p and Cdr2p. A number of additional
compounds (14–17) demonstrated greater antifungal activity
against all yeast isolates (MICs ranging from 2.4 to 24), as com-
pared to 1–4. However, in several cases antifungal activity against
molds was minimal, Table 5.
Interestingly, most of the compounds exhibited comparable
MIC values for both C. glabrata isolates (Table 2 and 4), suggesting
that the carbazole compounds are generally less prone to efflux
pumping than the azoles, such as fluconazole.19,20 Time-kill studies
were carried out to investigate whether the antifungal activity
observed for 10 was fungistatic or fungicidal. Given the essential
nature of fungal H+-ATPase, it is anticipated that compounds tar-
geting H+-ATPase activity will promote fungicidal effects.21 Indeed,
exposure of C. albicans or wild-type C. glabrata cells to 10 resulted
in cell death comparable to that observed for amphotericin B
(AMB), which is a known fungicidal compound (Fig. 7).
It was subsequently evaluated whether or not the carbazoles
were able to prevent extracellular acidification of the surrounding
media by blocking the pumping activity of the H+-ATPase within
fungal cells.15 Compounds 10, 16 and 17, all of which were found
to be potent enzymatic inhibitors of the H+-ATPase, were also
potent inhibitors of proton export from fungal cells, while the con-
trol compound voriconazole did not affect proton transport
(Table 6). We then assessed the compounds for potential effects
on fungal intracellular ATP levels, which have previously been
shown to increase upon reduced H+-ATPase activity.15,22–24 The
Fig. 5. Kinetics of H+-ATPase inhibition by carbazole compounds. The initial rate of ATP hydrolysis catalyzed by S. cerevisiae H+-ATPase was determined by an NADH-coupled
ATPase assay, as described in the Supporting Information. The reaction was initiated by the addition of H+-ATPase-containing membranes (arrows with ‘‘H+-ATPase”) to a pH
7 buffer containing 5 mM ATP. At the indicated times the respective compounds were added to give the final compound concentrations shown in the figure and a final DMSO
concentration of 1.1%.
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Consequently, a decrease in intracellular ATP (iATP) levels will
indirectly affect H+-ATPase activity. To determine if the H+-
ATPase-inhibitory activity of the carbazoles was indirectly caused
by a decrease in ATP levels, iATP levels were determined upon
exposure to 7, 8, 10 and 15–17 (Table 6). In all cases, iATP levels
were increased in C. albicans cells exposed to carbazoles compared
to the untreated control. The most potent H+-ATPase inhibitor
compound 10 resulted in the largest iATP increase, and the least
potent H+-ATPase inhibitors 8 and 15 resulted in the lowest
increase in iATP. Compound 7 was a potent inhibitor of the enzy-
matic activity of the H+-ATPase (IC50: 2.6 and 6.9 mM, Table 2),
but was not very effective in preventing extracellular acidification
from whole fungal cells and resulted only in slight increase in iATP.
Compound 7 also displayed poor antifungal activity, similarly to
the related compounds 18 and 19, suggesting that the morpholino
R4 substitution in 7, 18 and 19 result in poor H+-ATPase inhibition
within whole fungal cells. This implies that the carbazoles need to
pass the fungal membrane to inhibit the H+-ATPase and 7, 18 and
19 may have reduced membrane permeability. In summary, these
data support our working hypothesis that the carbazoles inhibit
the H+-ATPase in fungal cells, leading to reduced ATP hydrolysis
and a concomitant increase in intracellular ATP.
To further support the notion that the carbazole H+-ATPase
inhibitors were specific inhibitors of fungal growth, we tested the
effect of all fifteen compounds on the growth of two bacterial spe-
cies; the gram-positive Staphylococcus aureus and the gram-nega-
tive Escherichia coli. The MICs for these 15 compounds are
presented in Table 7. The only compound to exert potent low
micromolar antibacterial activity on both S. aureus and E. coli was
10, which from our ATPase activity experiments was shown to pos-
sess very potent broad-spectrum ATPase activity. Compound 16
and 17 were interesting as they were potent inhibitors of the
ATP hydrolysis in the enzymatic assay and potent H+-ATPase inhi-
bitors in whole fungal cell assay (iATP and extracellular acidifica-
tion). Assuming that carbazoles bind from the cytoplasmic site tothe H+-ATPase, these data indicate that 16 and 17 have good mem-
brane permeability. Given the potent H+-ATPase-inhibitory activity
of these compounds it is encouraging that they exhibited better
antifungal than antibacterial activity, supporting the notion that
H+-ATPase is a promising and unique target for antifungal drug
development.
In line with expectations from a fungal H+-ATPase inhibitor, we
show here that carbazoles that potently inhibit the H+-ATPase also
exhibit broad spectrum antifungal activity.15,21 Furthermore, these
compounds led to an increase in intracellular ATP levels and act in
a fungicidal manner, as evidenced by MFC and time-kill data. An
extensive number of carbazoles with a very diverse set of substitu-
tions were previously reported to exhibit large variations in their
biological activities.25–29 Of particular interest is that certain car-
bazoles, displaying a similar scaffold substitution to those reported
in this article, have previously been reported as antifungal agents,
but with no report on the antifungal mode of action.25 The halo-
genated carbazole wiskostatin was identified as an antifungal com-
pound,25 but is also known to be a potent inhibitor of actin
polymerization through inhibition of neural Wiskott-Aldrich syn-
drome protein (N-WASP) by interaction in a cleft in the regulatory
GTPase-binding protein.27 Furthermore, wiskostatin has been
reported as an inhibitor of DNA synthesis in vaccinia, the prototyp-
ical poxvirus.28 Carbazole compounds very similar to those
reported here have also been identified as inhibitors of the PI3K/
Akt/FOXO1a signaling pathway, and have been suggested to target
the ATP-binding sites of kinases.29 This, together with a general
ATPase inhibitory function of the carbazoles in the present work,
prompted us to investigate if these carbazoles act as H+-ATPase
inhibitors by blocking the nucleotide-binding site. Our data sug-
gest that this is not the case, as we observed that a 10-fold increase
of ATP did not interfere with the inhibitory activity of the com-
pound. The binding site of the carbazole in the H+-ATPase is more
likely to be located in the ion inlet cavity of the transmembrane
region, where the fungal H+-ATPase inhibitor and antimalarial
compound KAE609 is also suggested to bind.30 The binding cavity
Fig. 6. Compound dependence of the initial rate of H+-ATPase activity at 1 mM
(triangles) or 10 mM (circles) ATP. The initial rates following compound addition
deduced from experiments similar to those shown in Fig. 5 were normalized to the
maximal rate obtained at 10 mM ATP in the absence of compound (presence of 1.1%
DMSO) and plotted as a function of the compound concentration. The lines show
the best fits of the equation V = Vmax  (1  [cpd]h/(IC50h + [cpd]h)) to the data
(n = 3), giving the following IC50 values: compound 5, 1 mM ATP, 78.0 ± 14.9 mM;
compound 5, 10 mM ATP, 60.0 ± 14.2 mM; compound 7, 1 mM ATP, 29.7 ± 6.7 mM;
compound 7, 10 mM ATP, 16.8 ± 1.7 mM; compound 10, 1 mM ATP, 4.5 ± 0.5 mM;
compound 10, 10 mM ATP, 6.3 ± 1.2 mM.
Table 5
Mold growth inhibition data (n=3).
Compound Fungal Growth Inhibition MIC [mM]
Aspergillus flavus
ATCC MYA-1005
Aspergillus fumigatus
ATCC 13073
5 >75 >75
6 >75 >75
7 >75 >75
8 >75 75
9 >75 >75
10 12 3.7
11 >75 >75
12 >75 >75
13 >75 >75
14 >75 >75
15 75 24
16 24 41
17 24 24
18 >75 >75
19 >75 >75
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101
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C. albicans
DMSO
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C. glabrata
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10 (10 M)
10 (5 M)
Fig. 7. Time-kill data for C. albicans and C. glabrata cells (1  105 CFU/ml) incubated
with DMSO (final concentration 1%), 1 mM AMB, and 5 or 10 mM of compound 10.
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well-known binding pocket for other Ca2+-ATPase inhibitors31,32
and has also been proposed as the binding pocket for the chemi-
cally related tetrahydrocarbazoles, which are also H+-ATPase inhi-
bitors with antifungal activity.33
Of the compounds evaluated in this study compound 10was the
most potent inhibitor of the H+-ATPase in the ATP hydrolysis assay
and by far the most potent antifungal compound tested. Within
the first ten minutes of exposure to compound 10 fungal cells were
potently inhibited in extracellular acidification of the surrounding
media, and within thirty minutes a large increase in intracellular
ATPwasobserved. Fungicidal activitywasevident after 1 hexposure
of 10 (10 mM) in C. albicans and 3 h of exposure in C. glabrata. Com-
pound 10 and 15 are distinctlymore basic than all other compounds
tested. Interestingly, due to the molecular features, these com-
pounds also have the highest calculated LogP and lowest LogD val-
ues (Supporting Information), which influences membrane
permeability and solubility properties. Molecular electrostaticinteractions could potentially also benefit from these properties.
Compound 10 also differs from 15 by its the possibility to make an
intramolecular hydrogen bond in the N-1 group, which may greatly
facilitate diffusion throughmembranes. Both compound10 and car-
bazole analogues in which R3 is substituted H (instead of –OH)
appear to be better fungal inhibitors. It would therefore be prudent
to evaluate a compound 10 analogue with a substituted H in the R3
position in any future antifungal drug development program. Com-
pound10was also shown to exhibit potent antibacterial activity and
has previously been reported as a bactericidal agent, where it was
found to exhibit membrane damaging activity in the bacterial spe-
cies Pseudomonas aeruginosa.34,35
Table 6
iATP and extracellular acidification IC50 data. Compounds 7, 8, 10, 15, 16, 17 and
voriconazole tested at 20 mM for iATP.
Compound iATPa (nM) Extracellular acidificationb IC50
(mM)
C. albicans S. cerevisiae C. albicans
DMSO 38 ± 17 NA NA
7 93 ± 45 33.3 ± 0.6 22.2 ± 12.9
8 70 ± 25 11.1 ± 2.1 9.7 ± 6.8
10 491 ± 79* 2.1 ± 1.0 2.4 ± 1.2
15 53 ± 10 16.2 ± 2.6 13.1 ± 7.2
16 235 ± 70* 7.3 ± 0.4 9.5 ± 2.5
17 221 ± 54* 10.6 ± 4.5 9.0 ± 1.9
Voriconazole 37 ± 19 >75 >75
a Data show mean ± SEM with n = 5. One-way ANOVA to compare differences
between iATP levels upon compound exposure and DMSO control (* >95% confi-
dence interval).
b IC50 is determined as the concentration that results in 50% inhibition of the
media acidification normalized to the response from glucose-activated versus non-
glucose-activated cells. Data show mean ± SEM with n = 3. NA: Not applicable.
Table 7
Bacterial growth inhibition data (n=3).
Compound Escherichia coli
ATCC 25922
Staphylococcus aureus
ATCC 29213
Growth inhibition MIC [mM]
5 >75 7.5
6 >75 41
7 >75 41
8 75 64
9 >75 75
10 20 2.9
11 >75 >75
12 >75 >75
13 >75 >75
14 75 7.5
15 75 24
16 75 24
17 75 24
18 >75 >75
19 >75 24
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H+-ATPase contributes at least partially to the antifungal mecha-
nism of action of these carbazole compounds. Longer periods of
fungal cell exposure to compound 10 (>30 min) could potentially
compromise the fungal membrane, as has been seen for bacterial
membranes.34,35 However, further studies are needed to address
whether the carbazoles presented here, are in fact able to compro-
mise the fungal membrane. Amphotericin B is a well-known anti-
fungal agent targeting the fungal membrane,36 and the
development of membrane-targeting agents is an emerging strat-
egy for treating persistent bacterial infections.37 Taking this into
account, carbazoles may represent a promising scaffold for the
development of new anti-infective therapies, as suggested by
others.32 Likewise, the fungal H+-ATPase has long been recognized
as a potential promising new antifungal target,21 and any future
drug discovery program using the carbazoles to target the
H+-ATPase should pay special attention to the potentially
membrane-compromising properties and the unspecific ATPase
inhibitory activity of the carbazoles in general.
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